Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return

Executive Summary

Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor

You may also be interested in...



Pfizer Sales Manager Sentenced for Bextra Off-Label Promotion

Department of Justice sentences former regional manager to pay $75,000 fine and probation; she is second Pfizer sales manager to face indictment.

Bextra Settlement Coming Soon: Industry Should Brace For Impact

Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement

Bextra Settlement Coming Soon: Industry Should Brace For Impact

Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel